Abstract
Adult men with cannabis dependence showed reduced symptoms of cannabis withdrawal and reported less cannabis use relative to placebo in a four‐week trial of the fatty acid amide hydrolase (FAAH) inhibitor PF‐04457845. The promising results of this Phase 2A trial suggest a potential new mechanism of action for the treatment of cannabis use disorder, the researchers stated. Study results were published online Dec. 6, 2018, in Lancet Psychiatry.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
